ES2211165T3 - Uso de un factor angiogenico para el tratamiento de angiopatias microvasculares. - Google Patents

Uso de un factor angiogenico para el tratamiento de angiopatias microvasculares.

Info

Publication number
ES2211165T3
ES2211165T3 ES99946776T ES99946776T ES2211165T3 ES 2211165 T3 ES2211165 T3 ES 2211165T3 ES 99946776 T ES99946776 T ES 99946776T ES 99946776 T ES99946776 T ES 99946776T ES 2211165 T3 ES2211165 T3 ES 2211165T3
Authority
ES
Spain
Prior art keywords
vegf
antibody
kidney
amino acid
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99946776T
Other languages
English (en)
Spanish (es)
Inventor
George F. Schreiner
Richard J. Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Scios LLC
Original Assignee
University of Washington
Scios LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Scios LLC filed Critical University of Washington
Application granted granted Critical
Publication of ES2211165T3 publication Critical patent/ES2211165T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES99946776T 1998-09-09 1999-09-09 Uso de un factor angiogenico para el tratamiento de angiopatias microvasculares. Expired - Lifetime ES2211165T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US9969498P 1998-09-09 1998-09-09
US99694P 1998-09-09
US12640699P 1999-03-26 1999-03-26
US126406P 1999-03-26
US12661599P 1999-03-27 1999-03-27
US126615P 1999-03-27

Publications (1)

Publication Number Publication Date
ES2211165T3 true ES2211165T3 (es) 2004-07-01

Family

ID=27378887

Family Applications (2)

Application Number Title Priority Date Filing Date
ES99946776T Expired - Lifetime ES2211165T3 (es) 1998-09-09 1999-09-09 Uso de un factor angiogenico para el tratamiento de angiopatias microvasculares.
ES99968631T Expired - Lifetime ES2216630T3 (es) 1998-09-09 1999-09-09 Metodos de tratar la hipertension dependiente de la sal.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES99968631T Expired - Lifetime ES2216630T3 (es) 1998-09-09 1999-09-09 Metodos de tratar la hipertension dependiente de la sal.

Country Status (13)

Country Link
US (3) US6352975B1 (https=)
EP (2) EP1112083B1 (https=)
JP (2) JP2002524421A (https=)
AT (2) ATE260675T1 (https=)
AU (2) AU5910599A (https=)
BR (2) BR9913564A (https=)
CA (2) CA2340320C (https=)
DE (2) DE69912815T2 (https=)
DK (2) DK1112083T3 (https=)
ES (2) ES2211165T3 (https=)
IL (2) IL141687A0 (https=)
PT (2) PT1109571E (https=)
WO (2) WO2000013703A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352975B1 (en) * 1998-09-09 2002-03-05 Scios Inc. Methods of treating hypertension and compositions for use therein
US6783954B2 (en) * 1999-03-05 2004-08-31 Compugen Ltd. VEGF nucleic acid and amino acid sequences
IL148674A0 (en) * 1999-11-02 2002-09-12 Genentech Inc Modulation of enos activity and therapeutic uses thereof
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
DE60235761D1 (de) 2001-08-01 2010-05-06 Univ Bristol Clifton Isoform des vegfs
EP1427323A4 (en) * 2001-08-20 2004-09-15 Univ Virginia USE OF S-NITROSOTHIOL SIGNALING TO TREAT BREATH CONTROL DISORDERS
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
US7795213B2 (en) 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
US20030171556A1 (en) * 2001-12-13 2003-09-11 Chi-Bom Chae Beta-amyloid binding factors and inhibitors thereof
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
JP2006068401A (ja) * 2004-09-03 2006-03-16 Kyushu Institute Of Technology 人工血管
CN101277704A (zh) * 2005-04-12 2008-10-01 因特拉迪格姆公司 用于治疗癌症及其它新血管生成疾病的RNAi治疗剂的组合物和方法
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
US8440619B2 (en) * 2005-08-31 2013-05-14 National University Corporation Kagawa University Utilization of hypertension/hypercardia-preventing effect of D-allose
ES2600781T3 (es) * 2008-12-04 2017-02-10 Curna, Inc. Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf
GB0921525D0 (en) * 2009-12-08 2010-01-27 Isis Innovation Product and method
WO2018183625A1 (en) 2017-03-30 2018-10-04 Wake Forest University Health Sciences Methods of treatment for kidney disease
CN113418940B (zh) * 2021-06-24 2023-03-14 电子科技大学 一种基于x射线示踪颗粒的检测方法及检测装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456550A (en) 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
ATE152626T1 (de) 1989-03-24 1997-05-15 Univ California Endothelialer zellwachsfaktor, isolierung und expression
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5219739A (en) 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5240714A (en) * 1989-08-29 1993-08-31 Rof Jose M S Non-digoxin-like Na+, K+ -ATPase inhibitory factor
US5318957A (en) * 1992-09-02 1994-06-07 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating angiogenesis
KR100695590B1 (ko) * 1996-11-01 2007-03-14 아크 테라퓨틱스 리미티드 산화질소 또는 프로스타시클린 생산을 자극하는 약제의 치료학적 용도 및 전달 기구
US6485942B1 (en) * 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
US6352975B1 (en) * 1998-09-09 2002-03-05 Scios Inc. Methods of treating hypertension and compositions for use therein

Also Published As

Publication number Publication date
IL141687A0 (en) 2002-03-10
WO2000013702A3 (en) 2000-09-08
CA2340728C (en) 2007-11-27
WO2000013702A2 (en) 2000-03-16
CA2340320A1 (en) 2000-03-16
JP2002532382A (ja) 2002-10-02
DE69912815T2 (de) 2004-10-21
CA2340728A1 (en) 2000-03-16
JP2002524421A (ja) 2002-08-06
BR9913564A (pt) 2001-05-22
ATE260675T1 (de) 2004-03-15
DE69915310T2 (de) 2005-03-10
US20020193288A1 (en) 2002-12-19
WO2000013703A2 (en) 2000-03-16
IL141686A0 (en) 2002-03-10
ATE253934T1 (de) 2003-11-15
BR9913533A (pt) 2001-06-05
DK1109571T3 (da) 2004-06-21
DK1112083T3 (da) 2004-03-08
EP1109571B1 (en) 2004-03-03
AU5910599A (en) 2000-03-27
DE69912815D1 (de) 2003-12-18
CA2340320C (en) 2006-11-14
EP1112083A2 (en) 2001-07-04
EP1112083B1 (en) 2003-11-12
US6352975B1 (en) 2002-03-05
EP1109571A2 (en) 2001-06-27
ES2216630T3 (es) 2004-10-16
AU6028599A (en) 2000-03-27
PT1109571E (pt) 2004-05-31
DE69915310D1 (de) 2004-04-08
WO2000013702A9 (en) 2000-10-19
WO2000013703A3 (en) 2000-07-06
PT1112083E (pt) 2004-03-31
US20040224885A1 (en) 2004-11-11
WO2000013703A9 (en) 2000-06-02

Similar Documents

Publication Publication Date Title
ES2211165T3 (es) Uso de un factor angiogenico para el tratamiento de angiopatias microvasculares.
US7030083B2 (en) Treatment of eclampsia and preeclampsia
ES2234818T3 (es) Procedimiento para tratar canceres que expresan el factor de crecimiento endotelial d.
ES2429034T3 (es) Uso de antagonistas de ANGPTL3 para el tratamiento de enfermedades hepáticas
ES2281704T3 (es) Procedimientos y compuestos para inhibir el crecimiento de celulas neoplasicas.
JP2004307514A (ja) Ｈｇｆによる肝臓障害に対する保護
JP2013209408A (ja) 神経成長因子アンタゴニストを投与することによって骨癌の疼痛を処置するための方法
PT1263464E (pt) Utilização de anticorpos anti-tgf-beta antagonistas para tratar ou para prevenir a perda da função renal
CN102895663A (zh) 含有用于调节血管发育的egfl7拮抗剂的组合物及方法
US11446376B2 (en) Methods for treating heart failure using glucagon receptor antagonistic antibodies
US6677300B1 (en) Treatment of microvascular angiopathies
US20240050529A1 (en) Modulating lymphatic vessels in neurological disease
CN101970670A (zh) 使用egfl8拮抗剂抑制血管发生的方法
EP1417971A2 (en) Use of an angiogenic factor for the treatment of microvascular angiopathies
ES2671731T3 (es) Hipertensión pulmonar
BRPI0709411A2 (pt) método para tratamento de uma doença renal
HK1065947A (en) Use of an angiogenic factor for the treatment of microvascular angiopathies
EP1447089A2 (en) Methods of treating hypertension and compositions for use therein
ES2326978T3 (es) Procedimiento de tratamiento del carcinoma hepatocelular.
US20210009672A1 (en) Methods of treating or preventing liver fibrosis with inhibition of activins a & b
HK1068788A (en) Methods of treating hypertension and compositions for use therein
KR20240070640A (ko) 지방간 및 비알코올성 지방간염의 치료약
JP2002161049A (ja) 血管内膜肥厚抑制剤
HK1149205B (en) Methods for inhibiting angiogenesis using egfl8 antagonists
AU2011211408A1 (en) Compositions and methods comprising an EGFL7 antagonist for modulating vascular development